Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol LRIG1 contributors: mct - updated : 08-01-2020
HGNC name leucine-rich repeats and immunoglobulin-like domains 1
HGNC id 17360
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • leucine-rich repeats
  • Ig-like domains in its extracellular region
    • conjugated GlycoP
    HOMOLOGY
    interspecies homolog to murine Lig-1
    homolog to Drosophila Kekkon-1
    Homologene
    FAMILY
  • leucine-rich repeat and the immunoglobulin superfamily
    • CATEGORY receptor membrane
    SUBCELLULAR LOCALIZATION extracellular
        plasma membrane
    basic FUNCTION
  • playing a role as a growth and tumor suppressor
  • functioning as a cell type-specific adhesion molecule or receptor at the glial cell surface
  • playing a role in the nervous system in neuroglial differentiation, development, and/or maintenance of neural functions where it is expressed
  • plays an essential role in Met degradation
  • suppressor of Met function, serving to regulate cellular receptor levels by promoting Met degradation in a ligand- and cbl-independent manner
  • acting in a negative feedback loop to regulate the activity of RET receptor tyrosine kinase
  • endogenous inhibitor of RET receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF
  • negative regulator of growth factor signaling
  • possible role for LRIG1 and LRIG2 proteins in meningioma pathogenesis
  • LRIG1 and LRIG3 overlap prominently in the developing vestibular apparatus and simultaneous removal of both genes disrupts inner ear morphogenesis
  • LRIG genes appear to act both redundantly and independently, with LRIG2 emerging as the most functionally distinct family member
  • LRIG1 is a negative regulator of the STAT3-dependent inflammatory pathway
  • is an independent prognostic factor in patients with non-small cell lung cancer that could be important in future decision-making algorithms for adjuvant lung cancer treatment
  • important homeostatic role of LRIG1 in skin
  • essential role of LRIG1 in regulating morphogenic events that shape the hippocampal circuits
  • is a tumor suppressor and a negative regulator of several receptor tyrosine kinases
  • LRIG1 functions as a thyroid tumor suppressor
  • negatively regulates receptor tyrosine kinases and functions as a tumor suppressor
  • participate in the aggressive progression of several tumors, where its expression is frequently decreased
  • acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia
  • tumor suppressor in gastrointestinal tract and epidermis
  • represents a pleiotropic AR-regulated feedback tumor suppressor that functions to restrict oncogenic signaling from AR
    • CELLULAR PROCESS cell life, differentiation
    PHYSIOLOGICAL PROCESS development
    PATHWAY
    metabolism
    signaling signal transduction
    growth factor receptor
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • negative regulator of EGF receptor and its relatives, ERBB2, ERBB3, and ERBB4, and LRIG1-mediated receptor ubiquitination and degradation may contribute to the suppression of ErbB receptor function
  • interacting with MET (LRIG1 destabilizes the Met receptor in a cbl-independent manner)
  • capable of physically interacting with RET and LRIG1/RET association inhibits GDNF binding, recruitment of Ret to lipid rafts, receptor autophosphorylation, and mitogen-activated protein kinase (MAPK) activation in response to GDNF
  • USP8 is involved in deubiquitination of LRIG1, influencing the efficiency of MET degradation
  • LRIG1 physically interacts with NTRK2 and attenuates BDNF signaling
  • is a suppressor of various receptor tyrosine kinases, including RET
    • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral   deletion    
    in various cancers
    tumoral     --low  
    in renal cell carcinoma
    tumoral     --over  
    destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to hepatocyte growth factor
    tumoral     --over  
    suppresses malignant glioma cell growth by attenuating EGFR activity
    tumoral     --low  
    in squamous cell carcinoma of the uterine cervix, with high LRIG2 expression identified women with a very poor prognosis
    tumoral     --over  
    in prostate cancer
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • prognostic biomarker in non-small cell lung cancer
    • Therapy target
    SystemTypeDisorderPubmed
    cancerbrain 
    feedback negative attenuator of EGFR and could offer a novel therapeutic target to treat patients with malignant gliomas
    ANIMAL & CELL MODELS
  • Lrig1-deficient mice display morphological changes in proximal dendrite arborization and defects in social interaction